用L-743,872治疗小鼠克鲁斯念珠菌或光滑念珠菌感染。
Treatment of murine Candida krusei or Candida glabrata infection with L-743,872.
作者信息
Graybill J R, Bocanegra R, Luther M, Fothergill A, Rinaldi M J
机构信息
The University of Texas Health Science Center at San Antonio and Audie L. Murphy Memorial Veterans Administration Hospital, 78284, USA.
出版信息
Antimicrob Agents Chemother. 1997 Sep;41(9):1937-9. doi: 10.1128/AAC.41.9.1937.
Abstract
L-743,872 is a broad-spectrum pneumocandin antifungal drug developed by Merck Research Co., and in the present work it was evaluated in vivo in murine models of Candida krusei and Candida glabrata infection. Mice were infected intravenously with two isolates of C. krusei and treated with fluconazole or L-743,872. Fluconazole was beneficial only in immune-competent mice infected with isolate 94-2696. At > 0.5 mg/kg of body weight/day, L-743,872 was effective against both infecting isolates in immune-competent and immune-suppressed mice. Against C. glabrata, L-743,872 was effective, at doses > or = 0.5 mg/kg, in reducing fungal cell counts in the kidneys but not in the spleen. L-743,872 has significant potential for clinical development.
摘要
L-743,872是默克研究公司研发的一种广谱棘白菌素类抗真菌药物，在本研究中，对其在克鲁斯念珠菌和光滑念珠菌感染的小鼠模型中的体内效果进行了评估。将两株克鲁斯念珠菌静脉注射感染小鼠，并用氟康唑或L-743,872进行治疗。氟康唑仅对感染94-2696菌株的免疫健全小鼠有益。当体重剂量>0.5mg/kg/天时，L-743,872对免疫健全和免疫抑制小鼠体内的两种感染菌株均有效。对于光滑念珠菌，当剂量≥0.5mg/kg时，L-743,872可有效减少肾脏中的真菌细胞数量，但对脾脏中的真菌细胞数量无效。L-743,872具有显著的临床开发潜力。
相似文献
1
Treatment of murine Candida krusei or Candida glabrata infection with L-743,872.用L-743,872治疗小鼠克鲁斯念珠菌或光滑念珠菌感染。
Antimicrob Agents Chemother. 1997 Sep;41(9):1937-9. doi: 10.1128/AAC.41.9.1937.
2
In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species.新型抗真菌药L-743,872（一种 pneumocandin）对唑类敏感及耐药念珠菌属的体外活性
Antimicrob Agents Chemother. 1997 Jul;41(7):1612-4. doi: 10.1128/AAC.41.7.1612.
3
Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis.在氟康唑基础上加用卡泊芬净并不能改善小鼠念珠菌病的预后。
Antimicrob Agents Chemother. 2003 Jul;47(7):2373-5. doi: 10.1128/AAC.47.7.2373-2375.2003.
4
Treatment of murine disseminated candidiasis with L-743,872.用L-743,872治疗小鼠播散性念珠菌病。
Antimicrob Agents Chemother. 1997 Aug;41(8):1775-7. doi: 10.1128/AAC.41.8.1775.
5
Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods.氟康唑、卡泊芬净（MK0991）和阿尼芬净（LY 303366）单独及联合应用通过时间杀菌法对念珠菌属和新型隐球菌的抗真菌活性。
Diagn Microbiol Infect Dis. 2002 May;43(1):13-7. doi: 10.1016/s0732-8893(02)00361-9.
6
In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera.阿尼芬净和卡泊芬净对光滑念珠菌的体内疗效以及在血清存在下与体外效力的相关性。
Antimicrob Agents Chemother. 2007 May;51(5):1616-20. doi: 10.1128/AAC.00105-07. Epub 2007 Feb 16.
7
Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice.棘白菌素类药物卡泊芬净对环磷酰胺诱导的免疫抑制小鼠播散性曲霉病和念珠菌病的疗效。
Antimicrob Agents Chemother. 2000 Sep;44(9):2310-8. doi: 10.1128/AAC.44.9.2310-2318.2000.
8
In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance.念珠菌属对卡泊芬净的体外敏感性：四年全球监测
J Clin Microbiol. 2006 Mar;44(3):760-3. doi: 10.1128/JCM.44.3.760-763.2006.
9
Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans.棘白菌素LY303366、肺炎球菌素MK-0991和氟康唑对念珠菌属和新型隐球菌的体外活性比较。
Antimicrob Agents Chemother. 1997 Sep;41(9):1957-60. doi: 10.1128/AAC.41.9.1957.
10
Candida and candidaemia. Susceptibility and epidemiology.念珠菌与念珠菌血症。药敏性与流行病学。
Dan Med J. 2013 Nov;60(11):B4698.
引用本文的文献
1
CRISPR-Cas9 approach confirms Calcineurin-responsive zinc finger 1 (Crz1) transcription factor as a promising therapeutic target in echinocandin-resistant Candida glabrata.CRISPR-Cas9 方法证实钙调神经磷酸酶反应锌指蛋白 1（Crz1）转录因子是棘白菌素耐药光滑念珠菌有前途的治疗靶点。
PLoS One. 2022 Mar 18;17(3):e0265777. doi: 10.1371/journal.pone.0265777. eCollection 2022.
2
Promising antifungal activity of new oxadiazole against Candida krusei.新噁二唑类化合物对克柔念珠菌具有良好的抗真菌活性。
PLoS One. 2020 Jan 14;15(1):e0227876. doi: 10.1371/journal.pone.0227876. eCollection 2020.
3
Investigation of the function of Candida albicans Als3 by heterologous expression in Candida glabrata.通过在光滑念珠菌中异源表达研究白念珠菌 Als3 的功能。
Infect Immun. 2013 Jul;81(7):2528-35. doi: 10.1128/IAI.00013-13. Epub 2013 Apr 29.
4
Caspofungin in combination with amphotericin B against Candida parapsilosis.卡泊芬净联合两性霉素B治疗近平滑念珠菌感染
Antimicrob Agents Chemother. 2007 Mar;51(3):941-5. doi: 10.1128/AAC.00880-06. Epub 2006 Dec 11.
5
Effects of caspofungin against Candida guilliermondii and Candida parapsilosis.卡泊芬净对季也蒙念珠菌和近平滑念珠菌的作用。
Antimicrob Agents Chemother. 2006 Aug;50(8):2719-27. doi: 10.1128/AAC.00111-06.
6
Assessment of the paradoxical effect of caspofungin in therapy of candidiasis.卡泊芬净治疗念珠菌病时矛盾效应的评估。
Antimicrob Agents Chemother. 2006 Apr;50(4):1293-7. doi: 10.1128/AAC.50.4.1293-1297.2006.
7
Caspofungin: the first agent available in the echinocandin class of antifungals.卡泊芬净：棘白菌素类抗真菌药物中的首个可用药物。
Proc (Bayl Univ Med Cent). 2002 Jan;15(1):97-9. doi: 10.1080/08998280.2002.11927822.
8
Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.通过联合使用脂质体两性霉素B与卡泊芬净或米卡芬净治疗免疫抑制小鼠的光滑念珠菌感染。
Antimicrob Agents Chemother. 2005 Dec;49(12):4895-902. doi: 10.1128/AAC.49.12.4895-4902.2005.
9
Caspofungin: a review of its use in the treatment of fungal infections.卡泊芬净：其在真菌感染治疗中的应用综述
Drugs. 2005;65(14):2049-68. doi: 10.2165/00003495-200565140-00009.
10
Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome.食管念珠菌病或侵袭性念珠菌病患者分离株的卡泊芬净药敏试验：最低抑菌浓度与治疗结果的关系。
Antimicrob Agents Chemother. 2005 Sep;49(9):3616-23. doi: 10.1128/AAC.49.9.3616-3623.2005.
本文引用的文献
1
Fluconazole resistance in Candida glabrata.光滑念珠菌对氟康唑的耐药性
Antimicrob Agents Chemother. 1993 Sep;37(9):1962-5. doi: 10.1128/AAC.37.9.1962.
2
Correlation between in vitro and in vivo activity of antifungal agents against Candida species.抗真菌药物对念珠菌属的体外和体内活性之间的相关性。
J Infect Dis. 1994 Aug;170(2):384-9. doi: 10.1093/infdis/170.2.384.
3
A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.一项比较氟康唑与两性霉素B治疗非中性粒细胞减少患者念珠菌血症的随机试验。念珠菌血症研究组与国立研究所。
N Engl J Med. 1994 Nov 17;331(20):1325-30. doi: 10.1056/NEJM199411173312001.
4
Resistance of Candida species to fluconazole.念珠菌属对氟康唑的耐药性。
Antimicrob Agents Chemother. 1995 Jan;39(1):1-8. doi: 10.1128/AAC.39.1.1.
5
Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis.水溶性半合成肺念珠菌素L-733,560的抗真菌活性增强，这是由于其对细胞壁合成的抑制作用增强所致。
Antimicrob Agents Chemother. 1994 Dec;38(12):2750-7. doi: 10.1128/AAC.38.12.2750.
6
Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.利用播散性曲霉病、念珠菌病和隐球菌病小鼠模型对水溶性棘白菌素类似物L-733560、L-705589和L-731373进行评估。
Antimicrob Agents Chemother. 1995 May;39(5):1077-81. doi: 10.1128/AAC.39.5.1077.
7
In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373.新型水溶性L-705589与L-731373杂交体——抗真菌药L-733560的体外评价
Antimicrob Agents Chemother. 1995 May;39(5):1070-6. doi: 10.1128/AAC.39.5.1070.
8
Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata.光滑念珠菌中因能量依赖型药物外排导致的氟康唑耐药性。
Antimicrob Agents Chemother. 1995 Aug;39(8):1696-9. doi: 10.1128/AAC.39.8.1696.
9
Risk factors for hospital-acquired candidemia. A matched case-control study.医院获得性念珠菌血症的危险因素。一项配对病例对照研究。
Arch Intern Med. 1989 Oct;149(10):2349-53.
10
Fluconazole and Candida krusei fungemia.
N Engl J Med. 1991 Oct 31;325(18):1315.
Zotero 插件